Education
About Us
Working with TipRanks
Follow Us
BioAtla (BCAB)
NASDAQ:BCAB
Earnings Data
Report Date
Mar 19, 2026Before Open (Confirmed)
Period Ending
2025 (Q4)Consensus EPS Forecast
-0.24Last Year’s EPS
-0.3Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress in clinical trials, strategic transactions, and market potential for BioAtla's programs, with robust data supporting their CAB platform's potential. However, financial challenges were noted, including increased net loss and decreased cash reserves.Company Guidance
FDA Alignment on Phase Three Trial Design
BioAtla achieved FDA alignment on the phase three OSV registrational trial design for OPSCC, which includes a dual primary endpoints design for potential accelerated approval followed by full approval.
Development Milestone with Context Therapeutics
Achieved a development milestone under a license agreement with Context Therapeutics related to the dual CAB Nectin 4 TCE program, providing non-dilutive capital and further validating the CAB T cell engager platform.
Compelling Data from CAB Platform Programs
Presented compelling data for dual CAB EpCAM TCE and MACV programs, demonstrating potential for differentiated therapies for difficult-to-treat cancers.
Potential Strategic Transaction
BioAtla is in advanced stages to finalize a strategic transaction with a potential partner by year-end.
Strong Phase Two Data for OSV
Phase two data for OSV in late-line OPSCC patients showed an overall response rate of 45% and a median overall survival of 11.6 months, significantly higher than historical response rates and survival with standard therapies.
Market Opportunity for OSFI
OSFI has demonstrated clinical activity in HPV-positive OPSCC and is projected to achieve worldwide peak sales of $800 million in second-line and later OPS alone, with the total worldwide OPSCC market projected to reach $3 billion by 2032.
Progress in Dual CAB EpCAM T Cell Engager Program
Preliminary data from phase one trial in advanced adenocarcinomas indicate a manageable safety profile and encouraging signs of tumor reductions, with a confirmed partial response at 0.6 mg dose.
MEKV Program's Potential in Soft Tissue Sarcoma
Phase two trial data for MEKV showed a median overall survival of 21.5 months in soft tissue sarcoma patients, compared to 11.5 to 13.6 months for approved agents, with a manageable safety profile.
BCAB Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
BCAB Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Nov 13, 2025 | $0.66 | $0.79 | +19.70% |
Aug 07, 2025 | $0.38 | $0.35 | -7.89% |
May 06, 2025 | $0.48 | $0.45 | -6.25% |
Mar 27, 2025 | $0.39 | $0.37 | -5.13% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does BioAtla (BCAB) report earnings?
BioAtla (BCAB) is schdueled to report earning on Mar 19, 2026, Before Open (Confirmed).
What is BioAtla (BCAB) earnings time?
BioAtla (BCAB) earnings time is at Mar 19, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is BCAB EPS forecast?
BCAB EPS forecast for the fiscal quarter 2025 (Q4) is -0.24.
